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Abstract
AIM: To evaluate the factors involved in the impairment 
of health-related quality of life (HRQOL) in patients with 
celiac disease.
METHODS: A multicenter, cross-sectional prospective 
study was performed in patients with celiac disease 
who completed two HRQOL quest ionnaires: the 
gastrointestinal quality of life index (GIQLI) and the 
EuroQol-5D (EQ).
RESULTS: Three hundred and forty patients (163 
controlled with a gluten-free diet, and 177 newly 
diagnosed with a normal diet) were included. The GIQLI 
score was significantly better in patients on a gluten-
free diet (GFD) than in non-treated patients on their 
usual diet, both in terms of the overall score (3.3 vs  2.7, 
respectively; P  < 0.001), as well as on the individual 
questionnaire dimensions. Both the preference value of 
the EQ as the visual analogue scale were significantly 
better in treated than in non-treated patients (0.93 vs  
0.72 P  < 0.001 and 80 vs  70 P  < 0.001, respectively). 
Variables significantly associated with a worse HRQOL 
score were female gender, failure to adhere to a GFD, 
and symptomatic status.
CONCLUSION: In untreated celiac disease, the most 
important factors that influence patient perception of 
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health are the presence of symptoms and a normal diet. 
HRQOL improves to levels similar to those described in 
the general population in celiac disease patients well 
controlled with a GFD.
© 2008 WJG. All rights reserved.
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INTRODUCTION
Celiac disease (CD) is a chronic immuno-inflammatory 
enteropathy that appears in genetically predisposed 
patients. Patients with this disease develop characteristic 
small-intestinal-mucosal changes, due to hypersensitivity 
to gluten. Several epidemiological factors, including a 
dramatic increase in the diagnosis of  CD[1] and changes 
in its presentation, with the appearance of  atypical forms, 
that may even mimic functional diseases, as well as the 
fact that it affects people of  any age[2] mean that CD is 
currently considered a common and important health-
care problem. It affects approximately 1%-2% of  adults in 
Western European populations[3].
Although the understanding of  the immunology and 
physiopathology of  CD is extensive[4,5], the impact of  
the disease from the patient’s point of  view has received 
less attention. The chronic nature of  the condition, 
together with the limitations imposed by the need to 
follow a permanent restrictive diet, substantial numbers 
of  physician visits, the risk of  associated diseases and 
potential complications, mean that CD can have a 
considerable negative impact on health-related quality 
of  life (HRQOL). Due to the lack of  disease-specific 
instruments to measure HRQOL in CD patients, generic 
questionnaires, such as the SF-36 or EuroQol-5D (EQ), 
have been used. Overall perception of  HRQOL is rated 
as bad or fair by 63% of  patients before diagnosis of  CD, 
and improves to 77% after treatment[6]. However, at least 
one study has indicated that treated CD patients rate their 
overall well-being, as measured with a visual analog scale 
(VAS), quite highly, with 83.6% of  patients being rated as 
'very well' or 'well'[7]. Apart from dietary treatment, other 
factors have been suggested to influence the HRQOL 
in CD patients. Some disease-related factors, such as the 
presence of  symptoms or associated co-morbidity, as 
well as the type of  diagnosis used (symptom-detected vs 
screening-detected), have also been shown to impair CD 
patients’ HRQOL[8,9]. Non-disease-related factors, such as 
female gender, also have a negative impact on HRQOL[10], 
although this is also true in other chronic diseases[11]. The 
impairment of  HRQOL in untreated celiac disease and its 
improvement after treatment with a gluten-free diet (GFD), 
has been confirmed using generic multidimensional 
HRQOL measures[12]. However, there is no agreement 
as to whether the HRQOL of  treated CD patients is 
similar[8,13,14] or not[15,16] to that of  the general population.
The aims of  the present study were to measure and 
compare the HRQOL in treated and untreated CD patients 
using condition-specifi c and generic measures of  HRQOL, 
and to analyze the factors impacting on HRQOL in these 
patients. A further objective was to compare scores on 
the generic measure of  HRQOL for the two study groups 
with general population reference scores for the same 
instrument (EQ). To this end, we performed a multicenter 
study in a representative sample of  patients from different 
parts of  Spain, including both large and small cities, and 
both island and mainland regions.
MATERIALS AND METHODS
Study subjects
Subjects were adult outpatients with CD who attended 
the Digestive Services Units of  seven different Spanish 
hospitals, over a one-year period. Diagnosis was based on 
current serological and histological criteria[17]. A total of  340 
CD patients were included. At the time of  inclusion, patients 
were stratifi ed into two groups, according to whether they 
were already following a GFD (GFD group) or whether 
they had not yet started on the GFD (pretreatment group).
Procedure
All patients completed a questionnaire on demographic 
details, current symptoms, information on the disease, 
and issues related to the GFD. They also completed the 
Gastrointestinal Quality of  Life Index (GIQLI) questionnaire 
and the EQ, two generic HRQOL instruments.
Patient compliance following the GFD was measured 
using an adapted version of  the self-administered question-
naire developed by Morisky et al[18]. The questionnaire 
consisted of  four items which measure the degree of  
treatment compliance, answered using dichotomous response 
options (yes/no). Two questions asked about unintentional 
lack of  compliance (“sometimes I forget my diet/sometimes 
I do not comply carefully with my diet”), while the other two 
questions dealt with intentional lack of  compliance (“when I 
feel well I sometimes discontinue my diet/when not feeling 
well I sometimes discontinue my diet”). If  either question 3 
or 4 was answered affi rmatively, the patient was considered 
to have voluntarily discontinued his or her diet. If  either 
question 1 or 2 was answered in the affi rmative, the patient 
was considered to have involuntarily neglected or forgotten 
his or her diet. This questionnaire was originally developed 
to measure compliance with medication, and was adapted for 
use in the current population by substituting drugs with GFD. 
In a previous study[2], many patients suggested that they never 
forgot about their diet; for that reason, a fifth option was 
added to the scale (“I never forget about my diet”). Patients 
checking this answer were considered good compliers.
In an ancillary study, 17 patients from the pre-treatment 
group completed the questionnaires both at inclusion, when 
they had not yet started on the GFD, and at least 6 mo 
following treatment with GFD.
HRQOL assessment  
HRQOL was assessed using two generic questionnaires. 
GIQLI is a self-administered questionnaire designed to 
assess HRQOL in patients with gastrointestinal diseases. It 
was chosen because it has been translated and validated for 
use in Spain[19]. The GIQLI consists of  36 items grouped 
into five domains of  health (gastrointestinal symptoms, 
physical dysfunction, social dysfunction, emotional 
dysfunction and treatment effects). Responses are scored 
on a 4-point Likert scale, in which 4 corresponds to the 
highest level of  functioning. The instrument produces fi ve 
dimension scores and an overall score ranging from 0 to 4, 
with a higher score refl ecting better HRQOL.
EQ is a short self-administered generic utility measure 
that provides both a descriptive profi le and an overall index 
for HRQOL. The EQ includes fi ve dimensions (mobility, 
personal care, daily activities, pain and anxiety-depression) 
answered on a 3-point scale ranging from no problems 
(level 1) to extreme problems (level 3). Combining one level 
of  severity from each of  the five dimensions generates 
a number of  discrete health states that can be assigned 
preference values ranging from 0, which represents worst 
health status, to 1 (best health status). The EQ also includes 
a VAS that ranges from 0 (worst imaginable health status) 
to 100 (best imaginable health status), on which patients 
were asked to mark the point that best refl ected their health 
status on the day of  the interview. The EQ has also been 
translated and validated in Spanish[20]. As a reference, normal 
values for a representative sample of  12 245 members of  
the Spanish general population also exist for the EQ, and 
we used these as a control for the patients included in the 
present study[21,22].
Statistical analysis
The Kolmogorov-Smirnov test showed that most of  
the study variables did not have a normal distribution. 
Descriptive analyses of  socio-demographic, clinical and 
HRQOL data were therefore performed using medians 
and 25th and 75th percentiles. Qualitative variables were 
described as proportions. Comparisons between variables 
were performed using the Mann-Whitney U, Kruskal-
Wallis or Fisher tests as appropriate. In the pre-treatment 
group, HRQOL was also analyzed depending on whether 
the diagnosis was performed on the basis of  symptoms or 
on positive serology.
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Three multiple linear regression models were developed 
to identify independent variables that infl uence HRQOL. 
Dependent variables in the three models were the overall 
GIQLI score, the EQ preference value index, and the 
EQ VAS scores. Independent variables in all models were 
GFD, sex, age, duration of  symptoms, and the binary 
variables were existence of  symptoms and presence of  
CD-associated diseases. Results obtained for the multiple 
linear regression model were the regression coefficient, 
t-test statistics, P values, and the variance infl ation factor. 
The t test established whether the independent variables 
contributed to predicting the dependent variables. Higher 
t-test values indicate that the independent variable more 
strongly predicts the dependent variable. It has been 
considered that each independent variable contributes to 
predicting the dependent variable when P < 0.05. The 
variance inflation factor, a measure of  multicollinearity, 
measures the inflation of  the standard error of  each 
regression coeffi cient for an independent variable due to 
redundant information in other independent variables. If  
the variance infl ation factor is 1.0, there is no redundant 
information in the other independent variables. The level 
of  statistical signifi cance for the multiple regression model 
was set at P < 0.05.
RESULTS
Patient and disease characteristics
A total of  340 patients from seven hospitals in different 
areas of  Spain were included. Table 1 summarizes the 
socio-demographic and clinical characteristics, according 
to whether they were in the GFD group (n = 163) or the 
pre-treatment group (n = 177). 
There were no relevant differences in demographic 
characteristics between the two groups. Age ranged from 
15 to 78 years. Treated patients were younger than non-
treated patients [median age 37 (28-47) vs 44 (30-50) 
years, respectively; P < 0.05], but the difference was not 
considered clinically relevant. The sample characteristics 
were also in accordance with the results of  previous 
epidemiological studies of  CD in Spain[2], with patients 
being young adults and predominantly female and non-
smokers. Most patients lived in small to medium-sized 
cities, with < 500 000 inhabitants.
The duration of  disease since diagnosis was not 
evaluated in the normal diet group because they were 
included at the t ime of  diagnosis. There were no 
statistically signifi cant differences in duration of  symptoms 
before diagnosis of  CD between treated and pre-treated 
patients. The disease presented in the classic form in 47 
(32%) patients in the GFD group and in 13 (11%) patients 
in the normal diet group (P < 0.01). The most frequently 
presenting non-classical forms of  CD included anemia 
(32%), cutaneous lesions (9%), and hypertransaminasemia 
(6%). Approximately 40% of  patients had associated 
diseases, such as thyroid diseases (7%), selective IgA 
defi ciency (3%), type I diabetes mellitus (5%), depression 
(11.1%), and chronic inflammatory arthropathy (8%). 
The percentage of  asymptomatic patients at inclusion 
was significantly higher in the treated GFD group than 
in the normal diet group (80% vs 33%, P < 0.01). In the 
GFD group, 117 patients (73%) were classified as good 
compliers on the basis of  their Morisky scores, 36 (22%) 
reported that they occasionally involuntarily neglected or 
forgot the diet, and eight (5%) had voluntarily discontinued 
the diet. Again in the GFD group, 47% of  patients 
reported complete disappearance of  symptoms since being 
on the diet, and 43% reported a signifi cant improvement 
in symptoms. Eight per cent of  patients reported a small 
improvement in symptoms, and 2% considered that their 
symptoms had not changed with treatment.
Description of HRQOL in CD
Figure 1 shows the overall score and the fi ve dimensions 
of  GIQLI for the GFD and pre-treatment groups. Patients 
in the GFD group reported signifi cantly (P < 0.001) better 
HRQOL than patients in the pre-treatment group for the 
overall score and the gastrointestinal symptoms, and in the 
physical, social and emotional dysfunction dimensions. 
Patients in the pre-treatment normal diet group scored 
best on GIQLI treatment effects domain [4.0 (3.0-4.0)], while 
the domains with the worst scores were physical dysfunction 
[2.3 (1.4-2.9)], emotional dysfunction [2.4 (1.8-3.0)], and 
gastrointestinal symptoms [2.8 (2.4-3.3)]. These results 
suggested that most impaired domains of  health in newly 
diagnosed CD patients were related to symptomatic and 
emotional dimensions. In GFD patients, the best scored 
domain was also the treatment domain [4.0 (3.0-4.0)] and the 
worst scored was emotional dysfunction [3.0 (2.4-3.4)], which 
Pre-treatment      GFD
Number   177   163
Age (yr)     44 (30-50)     37 (28-47)a 
Sex (male/female)     74/103     42/121
Smoking status
   Smoker     29 (16)     33 (25)
   Non-smoker   148 (84)   130 (75)
City of residence
   < 100 000 inhabitants     69 (43)     61 (39)
   100 000-500 000     72 ( 45)     65 (41)
   > 500 000     18 (12)     31 (20)
Family status
   Single     57 (33)     67 (42)
   Married   108 (63)     84 (53)
   Widowed       5 (4)       8 (5)
Educational level
   No studies       7 (4)       4 (2)
   Primary     56 (33)     38 (24)
   Secondary     55 (32)     61 (38)
   University studies     52 (31)     55 (36)
Occupational status
   Employee/self-employed     67 (41)     94 (62)
   Retired/pensioner     36 (22)     14 (9)
   Housewife     30 (18)     16 (10 )
   Student     12 (7)     19 (12)
   Unemployed     17 (12)     10 (7)
Disease duration (mo)       -     48 (24-84)
Duration of symptoms before diagnosis (mo)     24 (7-84)     12 (5-40)
Presence of symptoms at inclusion   118 (80)     52 (33)b
Presence of associated diseases at inclusion     42 (41)     41 (37)
Table 1  Socio-demographic and clinical characteristics of patients 
n  (%)
Results are expressed as medians and (25th and 75th percentiles) or absolute 
values and (percentage). aP < 0.05, bP < 0.01.
www.wjgnet.com
48        ISSN 1007-9327       CN 14-1219/R     World J Gastroenterol             January 7, 2008    Volume 14     Number 1
suggested that, although improved by treatment, the most 
sustained impairment affected the emotional dimension.
Median scores on the EQ preference value index and 
VAS are shown in Figure 2. The median EQ preference 
value was significantly higher in GFD patients than in 
the normal diet group [0.93 (0.85-1.0) vs 0.72 (0.58-1.0) 
respectively, P < 0.001]. The median VAS score was also 
significantly higher in GFD patients than in the normal 
diet group [80 (70-90) vs 70 (50-80) respectively, P < 0.001]. 
Presence (levels of  severity 2 and 3) or absence (level 1) 
of  problems for each EQ dimension for the GFD and 
normal diet patients are shown in Table 2. At diagnosis, 
the normal diet group patients reported problems with 
significantly greater frequently than those in the GFD 
group on all fi ve dimensions of  the EQ, which confi rmed 
that GFD improved patient perception of  health. In 
the normal diet group, problems were reported most 
frequently in the pain/discomfort (62%) and anxiety/
depression (54.5%) dimensions, and least frequently in the 
self-care dimension (10.2%). In the GFD group, problems 
were reported most frequently on the EQ anxiety/
depression dimension (33.9%), in consonance with the low 
score of  the emotional dimension in the GIQLI observed 
in this group of  patients.
Factors infl uencing HRQOL in CD
Table 3 shows the results of  the multiple regression 
analysis, which took the GIQLI overall score as a 
dependent variable for all patients. The analysis suggested 
that the presence of  symptoms, normal diet and female 
gender were the strongest determinants (P < 0.001) for a 
worse perception of  HRQOL.
Similar results were obtained using the linear regression 
analysis with the EQ preference value index (Table 4) 
and the EQ VAS (Table 5) as the dependent variables, 
and included the same independent variables as described 
earlier. Presence of  symptoms and normal diet represented 
signifi cant determinants of  worse HRQOL. In this case, 
the presence of  CD-associated diseases was also associated 
with poorer HRQOL.
In the pre-treated normal diet group, results of  the 
comparison of  patients diagnosed according to the presence 
of  symptoms or a positive serology (n = 26) are shown 
in Figure 3. HRQOL was significantly worse in patients 
diagnosed through symptoms rather than through serologic 
tests without observable symptoms. The worst HRQOL 
was, therefore, found in women who had been recently 
diagnosed due to the presence of  symptoms, who were in 
the normal diet group, and who had associated diseases.
In the GFD group, specific potential factors that may 
be related to HRQOL, such as compliance or response to 
Figure 1  Median global and dimension scores of GIQLI for GFD (circles) and 
untreated (triangles) patients. Scores were signifi cantly higher (P < 0.001) for all 
dimensions except treatment. bP < 0.001. 
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Figure 2  Median scores and 25th and 75th percentiles for the tariff and VAS of 
the EQ for GFD (white columns) and normal diet (grey columns). Scores were 
signifi cantly better (P < 0.001) for patients in the GFD group. bP < 0.001.
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Variable      Pre-treatment     Gluten-free diet
    No 
problems
    Some 
 problems
    No 
problems
  Some 
problems
Mobility 130 (74.3)   45 (25.7) 146b (90.1)  16 (9.9)
Self-care 158 (89.8)   18 (10.2) 161b (99.3)    1 (0.7)
Usual activities 113 (64.5)   62 (35.5) 135b (83.3)  27 (16.7)
Pain/Discomfort   67 (38) 109 (62) 117b (72.8)  45 (27.7)
Anxiety/Depression   80 (45.5)   96 (54.5) 107b (66.1)  55 (33.9)
Table 2  Description of presence or absence of problems for
each EQ dimension according to treatment  n  (%)
bP < 0.001.
Independent 
variable
t -test 
statistics
P  value Variance infl ation
        factor
Pretreatment/treatment   4.989 < 0.001              1.31
Age  -0.725     0.469              1.31
Gender (m/f)  -2.684     0.008              1.06
Smoking habit   1.038     0.301              1.02
Symptoms duration  -1.813     0.072              1.08
Presence of symptoms  -4.932 < 0.001              1.31
Associated diseases  -1.824     0.070              1.18
Table 3  Results of the multiple regression modeling with global 
GIQLI score as a dependent factor
Independent 
variable
 t-test 
statistics
  P value Variance infl ation 
        factor
Pretreatment/treatment    3.20     0.002              1.31
Age    0.44     0.663              1.20
Gender (m/f)   -1.12     0.261              1.07
Smoking habit    0.58     0.559              1.02
Symptoms duration   -1.61     0.109              1.08
Presence of symptoms   -5.09  < 0.001              1.31
Associated diseases   -2.61     0.01              1.18
Table 4  Results of the multiple regression modeling with the 
preference value of the EQ score as the dependent factor
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diet, were assessed. There were no statistically significant 
differences in median overall GIQLI score between patients 
classified as good compliers (n = 117), and those who 
involuntarily neglected or forgot their diet (n = 36), and 
those who had voluntarily interrupted their diet (n = 8) 
[median GIQLI (IQR) scores, 3.3 (2.8-3.5), 3.2 (2.8-3.4), 
and 2.9 (2.6-3.3), respectively]. In contrast, GIQLI scores 
were signifi cantly higher (better HRQOL) in the 73 patients 
who reported achieving complete control of  symptoms 
with the GFD, than in patients reporting a partial or non-
response (n = 84) [3.4 (3.1-3.6)] vs [3.0 (2.7-3.4), P < 0.001]. 
With reference to the potential effect of  GFD duration on 
HRQOL, the duration of  treatment and GIQLI overall 
score were slightly correlated (r = 0.19, P < 0.05) according 
to the Spearman rank correlation test. Similar correlation 
was observed with the EQ preference value index and the 
EQ VAS (r = 0.20, P < 0.05 and r = 0.15, P = NS).
Intensity of impairment of HRQOL in CD
Although statistical comparisons between CD patients’ 
EQ scores and those described for the Spanish general 
population (median preference value of  1.0 and VAS score 
of  80) were not performed, it seems apparent that treated 
patients do not have different preference values and VAS 
scores to the Spanish general population. In contrast, 
preferences and VAS scores of  the normal diet group were 
worse than those of  the general population. According to 
the distribution of  EQ VAS scores in the Spanish general 
population (21), CD patients  perceive their health as 
good to excellent (VAS scores between 70 and 100), while 
untreated patients with newly diagnosed CD have VAS 
scores corresponding to fair health.
Changes in HRQOL of CD before and after treatment
Seventeen newly diagnosed patients [11 women, six men, 
median age 48 (34-60) years] completed the HRQOL 
questionnaire before initiating treatment and after 6-23 mo 
with GFD. Paired comparisons using the Wilcoxon signed 
rank test showed that treatment improved signifi cantly the 
GIQLI overall score [from a median of  2.6 (2.3-3.0) to 2.9 
(2.7-3.4), P <0.001] and the VAS score [from 70 (55-70) 
to 77 (70-87) respectively, P < 0.01]. However, the median 
EQ preference value increase after treatment did not reach 
statistical significance [0.85 (0.69-1.0) to 0.87 (0.71-1.0), 
P = NS].
DISCUSSION
To analyze how CD affects HRQOL and to determine 
which factors are associated, we administered two generic 
instruments to measure HRQOL in two groups of  CD 
patients: 163 patients following a GFD and 177 newly 
diagnosed patients who were on a normal diet. A potential 
limitation of  the study is a selection bias for patients 
because we only included hospital-controlled patients. 
Results on the GIQLI and EQ questionnaires suggest that 
the HRQOL of  untreated recently diagnosed CD patients 
is significantly impaired, on almost all of  the dimensions 
on both instruments and on the overall score. It is not 
surprising then that these patients’ assessment of  their 
overall health on the EQ should be equivalent to a rating of  
only fair health. Patients before starting a GFD only scored 
well on the treatment effects dimension on the GIQLI 
questionnaire. Although these patients have not initiated 
the GFD, the highly-scored dimension was treatment, 
probably because this item refers to “feeling let down by 
treatment effects” and most patients have received prior 
diet or drug recommendations, or because patients tend to 
respond neutrally to items in this domain. By contrast, CD 
patients controlled with a GFD reported signifi cantly better 
HRQOL, and in fact had EQ scores that were very similar 
to those of  a representative sample of  the Spanish general 
population[21,22]. These results study are in line with those 
reported very recently by the Canadian Celiac Association[23]. 
In that study, it was found that SF-12 summary scores for 
CD patients were similar to the normative Canadian data, 
except for females and newly diagnosed patients.
The importance of  adequate compliance with a GFD 
is confi rmed by the multivariate analysis, in which it was 
shown that GFD exerted a major infl uence on HRQOL, 
Figure 3  Median scores and 25th and 75th percentiles for the global GIQLI (left 
panel) and EQ index and VAS (right panel) in the pre-treated normal diet CD 
patients (white columns represents patients diagnosed due to symptoms and grey 
columns those diagnosed by serological tests). Scores were signifi cantly worse 
(P < 0.05) for patients diagnosed due to symptoms compared to those with 
isolated serologic tests. bP < 0.001.
Independent 
variable
  t-test 
statistics
 P value Variance infl ation
        factor
Pretreatment/treatment    2.97     0.003            1.37
Age    0.81     0.420            1.23
Gender (m/f)   -1.48     0.141            1.11
Smoking habit   -0.49     0.624            1.02
Symptoms duration   -2.71     0.007            1.08
Presence of symptoms   -5.99  < 0.001            1.40
Associated diseases   -2.50     0.013            1.17
Table 5  Results of the multiple regression modeling with the 
VAS of the EQ score as a dependent factor
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CD has a signifi cant negative impact on several domains 
of  HRQOL, and that HRQOL is more impaired in 
symptomatic patients and in those with CD-associated 
diseases. On the other hand, HRQOL improves to 
levels observed in the general population when CD is 
controlled with a GFD. From our observations, it can be 
concluded that the assessment of  HRQOL in CD patients 
is relevant because it improves physicians’ knowledge 
of  the implications of  the disease, and helps patients to 
recognize the general impact of  the disease. Additionally, 
the fact that patients following a GFD report similar levels 
of  HRQOL as members of  the general population should 
encourage patients to adhere to the GFD.
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Background
Celiac disease (CD) is a chronic immuno-infl ammatory enteropathy that appears 
in genetically predisposed patients, who develop characteristic small-intestinal-
mucosal changes, due to hypersensitivity to gluten. The chronic nature of the 
condition, together with the limitations imposed by the need to follow a permanent 
restrictive diet, substantial numbers of physician visits, the risk of associated 
diseases and potential complications, mean that CD can have a considerable 
negative impact on health-related quality of life (HRQOL). The impairment of 
HRQOL in untreated CD and its improvement after treatment with a gluten-free diet 
(GFD), has been suggested using generic multidimensional HRQOL measures.
Research frontiers
There is a lack of information relative to some areas in the research of HRQOL 
in CD. There is no agreement as to whether the HRQOL of treated CD patients 
reaches that of the general population, the factors involved in HRQOL impairment, 
and in the use of more specifi c instruments to measure the HRQOL of CD patients.
Innovations
Two instruments to measure HRQOL in two groups of CD patients: 163 patients 
following a GFD and 177 newly diagnosed patients who were on a normal diet 
containing gluten. Results on the gastrointestinal quality of life index GIQLI and 
EuroQol-5D EQ questionnaires suggested that the HRQOL of untreated, recently 
diagnosed CD patients was signifi cantly impaired, on almost all of the dimensions 
on both instruments and on the overall score. Patients, before starting a GFD, 
considered their overall health equivalent to a rating of only fair. CD patients 
controlled with a GFD reported signifi cantly better HRQOL, and in fact had EQ 
scores that were very similar to those of a representative sample of the Spanish 
general population. The importance of diet on CD was confi rmed in an ancillary 
study in which HRQOL was re-measured after at least 6 mo on GFD. Results of 
that ancillary study confirm that treatment of CD improves HRQOL. Our study 
also provided some evidence that symptom-detected patients had significantly 
lower overall scores on the GIQLI and on the EQ preference index than serologic-
detected patients, which suggested that the former had better self-perceived 
health on diagnosis. To determine the factors involved in HRQOL impairment in 
CD, a multivariate analysis using the condition-specifi c GIQLI or the generic EQ 
instrument was performed. Results of that analysis suggested that the variables 
signifi cantly associated with a worse HRQOL were female gender, failure to follow 
a GFD, and symptomatic status.
Applications
The results of the present study suggest that compliance with a GFD and 
adequate control of symptoms are decisive in terms that CD patients  may recover 
to satisfactory levels of self-perceived health. The assessment of HRQOL in CD 
patients is relevant because it improves physicians’ knowledge of the implications 
of the disease and helps patients to recognize the general impact of the disease. 
The fact that patients following a GFD reached similar levels of HRQOL as 
members of the general population should encourage patients to adhere to a GFD.
whether using the condition-specifi c GIQLI or the generic 
EQ instrument. To avoid the problem of  between-person 
variability in the determination of  the effect of  GFD on 
HRQOL, in a subgroup of  newly diagnosed patients, the 
HRQOL was re-measured after at least 6 mo on GFD. 
Results of  that ancillary study confirmed that treatment 
of  CD improves HRQOL. The multivariate analysis also 
indicated that the presence of  symptoms and comorbidity 
were other independent variables that significantly 
infl uenced HRQOL in CD patients. These results suggest 
that compliance with GFD and adequate control of  
symptoms are decisive, in terms that CD patients may 
recover to satisfactory levels of  self-perceived health. The 
duration of  improvements in HRQOL in CD patients 
following a GFD could not be deduced from our study, 
but it has been suggested that such improvements may be 
maintained for as long as 20 years[14]. 
Although our study confi rmed that a GFD improves 
symptoms, with 90% of  patients reporting a clinically 
significant improvement, as well as raising CD patients’ 
levels of  HRQOL to those reported by the general 
population, other studies, such as that by the Westchester 
Celiac Sprue Support Group have observed negative 
effects of  a GFD on HRQOL in areas such as dining out, 
travel and family life[24]. These aspects were not covered 
in depth by either of  the HRQOL instruments included 
here, and they should be considered for inclusion in future 
studies. 
Advances in the serologic diagnosis of  CD mean 
that the disease is recognized at increasingly early times, 
even in asymptomatic patients. Presumably as a result 
of  the absence of  symptoms in patients diagnosed by 
serologic screening, as opposed to patients diagnosed by 
clinical symptoms, it has been suggested that screening-
detected CD patients have better HRQOL than those 
diagnosed based on symptoms[10,25]. There is no agreement 
as to whether a GFD improves HRQOL independently 
of  whether diagnosis was based on serologic screening 
or on symptoms, with some evidence suggesting that 
improvements in HRQOL occur in both types of  
patients[25], and other evidence pointing out that they are 
only found in symptom-detected patients[10]. Our study also 
provides some evidence that symptom-detected patients 
have significantly lower overall scores on the GIQLI 
and on the EQ preference index than serologic-detected 
patients, which suggests that the former have better self-
perceived health on diagnosis. However, the nature of  the 
present study meant that it was not possible to determine 
whether diet-induced improvements in HRQOL were 
related or not to the type of  diagnosis.
The only non-disease-related variable that had a 
signifi cant infl uence on HRQOL was gender, with women 
scoring signifi cantly poorer on the GIQLI questionnaire. It 
has been suggested that in treated CD patients, low scoring 
of  SF-36 is confi ned to female patients[15]. However, in our 
study, the infl uence of  gender on HRQOL was less clear 
because, although female sex was a signifi cant independent 
variable for poorer perception of  HRQOL as measured 
by the GIQLI, the effect was not seen on either the EQ 
preference value index or on the EQ VAS.
Our results suggest that untreated newly diagnosed 
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Terminology
HRQOL has a recognized importance to evaluate, manage and follow patients 
with chronic diseases, such as CD. Different types of instruments for measuring 
HRQOL have been introduced, with the most important being the questionnaires. 
There are generic questionnaires and disease-specifi c questionnaires. Although 
a specific questionnaire for CD has recently been published, the most widely 
used instruments to measure HRQOL in CD are the generic questionnaires. 
GIQLI is a self-administered questionnaire designed to assess HRQOL in patients 
with gastrointestinal diseases. The GIQLI consists of 36 items grouped into 
five domains of health (gastrointestinal symptoms, physical dysfunction, social 
dysfunction, emotional dysfunction and treatment effects). Responses are scored 
on a 4-point Likert scale, in which 4 corresponds to the highest level of functioning. 
EQ is a self-administered generic utility measure that provides both a descriptive 
profi le and an overall index for HRQOL. The EQ includes fi ve dimensions (mobility, 
personal care, daily activities, pain and anxiety–depression) answered on a 3-point 
scale ranging from no problems (level 1) to extreme problems (level 3). Combining 
one level of severity from each of the five dimensions generates a number of 
discrete health states that can be assigned preference values ranging from 0, 
which represents worst health status, to 1 (best health status). The EQ also 
includes a VAS that ranges from 0 (worst imaginable health status) to 100.
Peer Review
This is a well designed study addressing an important aspect of celiac disease 
which adds considerably to what is already known.
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